[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618558":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":62,"collaborators":25,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":25,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":88,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Pulmovant, Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Comparator: inhaled mosliciguat","EXPERIMENTAL","Participants will receive inhaled mosliciguat daily for 16 weeks",[13,14],"Drug: inhaled mosliciguat","Device: Dry Powder Inhaler",{"label":16,"type":10,"description":17,"interventionNames":18},"Extension: inhaled mosliciguat","After Week 16, all participants will continue to receive inhaled mosliciguat through an Extension period",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","inhaled mosliciguat","Dose level 1, 2, or 3 for inhalation",[9,16],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"DEVICE","Dry Powder Inhaler","Dry powder inhaler for mosliciguat delivery",[9,16],[32],{"name":33,"affiliation":5,"role":34},"Ubaldo Martin, MD","STUDY_DIRECTOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Pulmovant","CONTACT","+1-919-462-1310","clinicaltrials@pulmovant.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Florida Lung, Asthma & Sleep Specialists\u002FClinical Research Specialists, LLC","RECRUITING","Kissimmee","Florida","34746","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-81.41667,28.30468,{"lat":54,"lon":53},[57],{"name":58,"role":38,"phone":59,"phoneExt":60,"email":61},"Guevara Lusmelys","407-507-2615","8","lusmelys@floridalungdoctors.com",{"type":63,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100618558","phase-2-a-study-of-mosliciguat-in-combination-with-inhaled-treprostinil-in-ph-ild-100618558",false,"NCT07333183","A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD","An Open-Label, Phase 2 Study Evaluating the Safety of Mosliciguat in Combination With Inhaled Treprostinil in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease","Inclusion Criteria:\n\n* Participants willing and able to provide informed consent\n* Participants on inhaled treprostinil\n* Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include:\n\n  1. Idiopathic interstitial pneumonia (IIP)\n  2. Chronic hypersensitivity pneumonitis\n  3. ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \\\u003C 70% of predicted\n* Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).\n* Ability to perform 6MWD ≥100 meters.\n\nExclusion Criteria:\n\n* Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).\n* Exacerbation of underlying lung disease within 28 days prior to randomization.\n* Initiation of pulmonary rehabilitation within 28 days prior to randomization.\n* Receiving \\>10 L\u002Fmin of oxygen supplementation by any mode of delivery at rest at Baseline.\n* History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.\n* Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.\n\nNote: Other inclusion and exclusion criteria may apply.","ALL","18 Years","85 Years",{"count":75,"type":76},20,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.",[82,83,84,85,86,87],"Pulmonary Hypertension","Interstitial Lung Disease (ILD)","Lung Diseases","Vascular Diseases","Cardiovascular Diseases","Fibrosis",[89,90,91,92],"PH","ILD","6 Minute Walk Test","mosliciguat","2026-04-18",{"date":95,"type":96},"2026-04-22","ACTUAL",{"date":98,"type":96},"2025-12-23",{"date":100,"type":76},"2028-01",{"name":5,"class":6},1]